Key Highlights From the PERSEUS and CASSIOPEIA Studies
Panelists discuss how recent pivotal trials like PERSEUS and CASSIOPEIA demonstrate superior outcomes with daratumumab-based quadruplet and triplet combinations compared with standard regimens in transplant-eligible newly diagnosed multiple myeloma patients, particularly showing improved progression-free survival when daratumumab is added to VRd (bortezomib, lenalidomide, and dexamethasone) or VTd (bortezomib, thalidomide, and dexamethasone) backbones.
Video content above is prompted by the following:
- Let’s begin our discussion with newly diagnosed multiple myeloma, specifically in patients who are transplant eligible. Can you briefly comment on recent updates surrounding combination therapies for transplant-eligible NDMM:
- Dara-VRd vs VRd
- Dara-VTd vs VTd
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
